Kardigan (KARD) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KARD | PCRX |
|---|---|---|
| Share price | $14.67 | $36.31 |
| Market cap | $1.37B | $1.45B |
| 1-day change | +3.31% | -0.22% |
| YTD return | — | +40.30% |
| 1-year return | — | +57.46% |
| 5-year return | — | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | — | 10.50 |
| EPS (TTM) | $-11.02 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $27.00 | $36.46 |
| 52-week low | $12.23 | $18.80 |
| Distance from 52-week high | -45.67% | -0.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +188.00% | -17.08% |
| Average volume | 487.54K | 1.03M |
| Shares outstanding | 93.50M | 39.91M |
| Employees | 241 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kardigan
KARD stock →Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 241 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
KARD vs PCRX FAQ
Which is bigger, Kardigan or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.37B for Kardigan (KARD).
Are Kardigan and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.